title: The reducing effects of tazifylline on histamine-induced bronchoconstriction in atopic asthmatics.
abstract: Percentage reductions in the peak flow rates to a standardized number of histamine inhalations were compared after 7 days of treatment with 10 mg bd tazifylline and after 7 days of placebo in a randomized crossover study in 11 male seasonal atopic asthmatics. After tazifylline, mean % reductions in peak flow rates were significantly lower than after placebo (p = 0.03). The effects of tazifylline had disappeared within 7 days of stopping treatment. Using a 50% decrease in bronchial reactivity as the criteria of "protection", 7 of the subjects were "protected" by tazifylline only and none by placebo only (p = 0.03).
authors.affiliation: Allergy Hospital, Helsinki University Central Hospital, Finland.
authors.forename: K
authors.initials: K
authors.lastname: Kiviranta
authors.forename: B
authors.initials: B
authors.lastname: Stenius-Aarniala
authors.forename: C
authors.initials: C
authors.lastname: Reuter
authors.forename: B
authors.initials: B
authors.lastname: Harlow
authors.forename: J
authors.initials: J
authors.lastname: Scott
mesh_terms: D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents; D006632:Histamine; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013806:Theophylline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D001993:Bronchodilator Agents; D006634:Histamine H1 Antagonists; D006632:Histamine; D013806:Theophylline; C048398:tazifylline